Robert W. Baird Increases Gilead Sciences (NASDAQ:GILD) Price Target to $95.00

Gilead Sciences (NASDAQ:GILD) had its price objective upped by Robert W. Baird from $80.00 to $95.00 in a report published on Thursday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on GILD. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, October 9th. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research report on Thursday. Cantor Fitzgerald raised their target price on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Thursday. Barclays boosted their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $91.50.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $1.34 on Thursday, hitting $96.57. 7,457,030 shares of the company traded hands, compared to its average volume of 5,289,753. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.32. The firm’s 50-day simple moving average is $85.30 and its 200 day simple moving average is $75.03. The company has a market cap of $120.22 billion, a P/E ratio of 1,072.94, a P/E/G ratio of 3.19 and a beta of 0.17. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 28.60% and a net margin of 0.45%. The company’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. Analysts expect that Gilead Sciences will post 3.76 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.19%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,437 shares of company stock worth $5,374,825. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. CarsonAllaria Wealth Management Ltd. increased its holdings in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $33,000. Finally, Cedar Wealth Management LLC lifted its holdings in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.